76661-24-0

Usage

Uses

Used in Pharmaceutical Synthesis:
2,5-dichloro-4-(3-nitrophenoxy)pyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications in treating diseases and disorders.
Used in Agrochemical Synthesis:
In the agrochemical industry, 2,5-dichloro-4-(3-nitrophenoxy)pyrimidine is utilized as an essential component in the production of fungicides and herbicides. Its incorporation into these products enhances their effectiveness in controlling plant diseases and unwanted vegetation, respectively.
Used in Medicinal Chemistry Research:
2,5-dichloro-4-(3-nitrophenoxy)pyrimidine is also employed in the field of medicinal chemistry for the exploration of its potential applications. Its versatile structure and potent biological activity make it a valuable compound for studying and developing new therapeutic agents and drug candidates.

Upstream product

• 100-02-7 4-nitro-phenol 
• 5750-76-5 2,4,5-trichloropyrimidine 
• 554-84-7 meta-nitrophenol 

Downstream Products

• 1213269-25-0 5-chloro-N-(2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)-4-(3-nitrophenoxy)pyrimidin-2-amine 
• 1254783-97-5 tert-butyl 4-(4-(5-chloro-4-(3-nitrophenoxy)pyrimidin-2-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1374641-74-3 3-((2,5-dichloropyrimidin-4-yl)oxy)aniline 
• 1374641-75-4 N-(3-((2,5-dichloropyrimidin-4-yl)oxy)phenyl)acrylamide 
• 1436851-28-3 C₂₈H₃₁ClN₆O₅ 
• 1436851-29-4 2-(4-(4-((4-(3-acrylamidophenoxy)-5-chloropyrimidin-2-yl)-amino)-3-methoxyphenyl)piperazin-1-yl)acetic acid 
• 1436851-31-8 C₃₆H₃₆ClN₉O₉S 
• 1436851-32-9 C₃₇H₃₈ClN₉O₉S 
• 1436851-33-0 C₄₀H₄₃ClN₁₀O₉S 
• 1436851-34-1 C₃₉H₄₀ClN₉O₉S 
• 1436851-35-2 C₃₇H₃₈ClN₉O₉S 
• 1436851-36-3 C₃₆H₃₅ClN₈O₁₀S 
• 1436851-37-4 C₃₇H₃₇ClN₈O₁₀S 
• 1436851-38-5 C₃₈H₃₉ClN₈O₁₀S 

Relevant academic research and scientific papers

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

Deuterated pyrimidine derivative with anti-cancer effect

The invention relates to a deuterated pyrimidine derivative with an anti-cancer effect, and belongs to the field of medicines. The invention aims to solve the problems that the in-vivo half-life period of an anti-cancer drug WZ4002 is too short, the blood

1,2-DITHIOLANE AND DITHIOL COMPOUNDS USEFUL IN TREATING MUTANT EGFR-MEDIATED DISEASES AND CONDITIONS

Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors

A series of thirty two anilinopyrimidines derived from WZ4002 has been synthesized and evaluated for percentage inhibition of six different EGFR kinases using LanthaScreen binding assay method (EGFR d746 – 750) or Z'LYTE assay method (EGFR-WT, EGFR d746 – 750, EGFR T790M, EGFR T790M L858R, EGFR C797S and EGFR T790M L858R C797S). Ortho-hydroxyacetamide 10 exhibited complete inhibition of all the six kinases at 10 μM. Against the triple mutant, EGFR T790M C797S L858R, compounds 9–12 exhibited complete inhibition at 10 μM and nearly complete inhibition at 1 μM. The target compounds were also evaluated using the MTT assay to determine their cytotoxic activity against human non-small cell lung cancer cells (PC9, PC9GR and H460) and mouse leukemic cells (Ba/F3 WT and Ba/F3T 3151). Overall, 7, 9–12, 30 and 31 were found to be the most potent compounds across all five cell lines.

Pyrimidine derivative, preparation method thereof, and application thereof in medicine

The invention relates to a pyrimidine derivative represented as the general formula (I), a preparation method thereof, and an application thereof in medicines. In particularly, the invention relates to a novel pyrimidine derivative, the preparation method

Method for preparing 2,5-dichloro-4-(3-nitrophenoxy) pyrimidine

The invention relates to a method for preparing a drug intermediate, in particular to a method for preparing 2,5-dichloro-4-(3-nitrophenoxy) pyrimidine.A reaction is conducted on 2,4,5-trichloropyrimidin and 3-nitrophenol to prepare and obtain the final p

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR

The clinical success of covalent kinase inhibitors in the treatment of EGFR-dependent non-small cell lung cancer (NSCLC) has rejuvenated the appreciation of reactive small molecules. Acquired drug resistance against first-line EGFR inhibitors remains the

Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors

Novel compounds 12a-i were synthesized and biologically evaluated. Several ones exhibited stronger inhibitory activity than gefitinib against EGFR L858R/T790M and antiproliferative effects on H1975 and HCC827 cells. The 3-aminopropamide in compounds like 12h could be converted to the active acrylamide in the presence of arginine. Importantly, 12h showed improved stability relative to compound 1 whose structure is same to 12h excepting an acrylamide moiety. Interestingly, 12i, a NO donating compound of 12h, showed more potent and selective inhibition than 12h on H1975 cells. Significantly, 12i produced high levels of NO in H1975 cells but not in non-tumorous 16HBE cells, and its inhibition was diminished by NO scavenger. Furthermore, 12i dose-dependently produced inhibitory effects on EGFR downstream signaling in H1975 cells.

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer

A series of hybrids (12a-k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited